10 sites
5 countries

Study goal

ECRAID-Prime is pleased to announce the addition of a third candidate treatment – LTX-109 intranasal spray – to its adaptive platform trial, which is already assessing the potential benefits of nitric oxide nasal spray and saline spray towards improving patient outcomes. 

The goal of this Phase 2A study is to evaluate whether LTX-109, produced by Pharma Holdings, accelerates the clearance of viral pathogens in outpatients with COVID-19 and COVID-like illness.  

Current status 

[to be updated]